Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  Toshiba Corp    6502   JP3592200004

TOSHIBA CORP (6502)

18
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

IBA : Links with Toshiba for Particle Therapy

04/18/2015 | 11:59pm US/Eastern

IBA (Ion Beam Applications S.A.) and Toshiba Corp. reported the signing of a global collaboration to expand access to advanced particle therapy worldwide.

According to a media release, Toshiba Medical Systems Corp. will become the distributor in Japan for ProteusONE, IBA's compact single- room proton therapy solution, and IBA will become the agent for Toshiba's Carbon Therapy Solutions outside Japan.

IBA and Toshiba will collaborate on activities such as customer education for ProteusONE and Toshiba's carbon therapy solutions.

The collaboration will also enable both organizations to mutually leverage their Operation and Maintenance (O&M) services.

Olivier Legrain, Chief Executive Officer of IBA commented: "This is an important step for IBA. A closer collaboration with a company of Toshiba's caliber and leadership will accelerate the expansion of proton therapy in Japan and the introduction of Toshiba's carbon therapy across the world. Carbon ion therapy is particularly suitable for treating radio-resistant tumors and allows for dose escalation, which is recommended in a number of clinical applications. Through this new collaboration, IBA will further strengthen its world leading position in proton therapy and will reaffirm its leading position in the delivery of the latest innovative cancer therapies worldwide."

Satoshi Tsunakawa, Chief Executive Officer of Healthcare Company, Toshiba Corp., said: "Proton and carbon therapies are among the most exciting technological advancements in the treatment of cancer. Toshiba looks forward to collaborating with IBA to enhance access to best-in-class technologies for both proton and carbon therapy centers. Guided by the principles of The Basic Commitment of the Toshiba Group, "Committed to People, Committed to the Future," this collaboration will give both our companies an enhanced set of tools to provide the best cancer treatment technologies."

Proton Therapy is considered an advanced and targeted cancer radiotherapy treatment due to its dose distribution and fewer side effects.

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated solutions for the diagnosis and treatment of cancer.

Toshiba Corp. channels capabilities in advanced electronic and electrical products and systems into five strategic business domains: Energy & Infrastructure, Community Solutions, Healthcare Systems & Services, Electronic Devices & Components, and Lifestyles Products & Services.

More Information:

http://www.iba-worldwide.com

http://www.toshiba.co.jp/index.htm

((Comments on this story may be sent to newsdesk@closeupmedia.com))

(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications

React to this article
Latest news on TOSHIBA CORP
04/18 IBA : Links with Toshiba for Particle Therapy
04/18 IBA : and Toshiba Ink Strategic Partnership
04/16 TOSHIBA : Develops Low Power Control Technology for Wearable Devices with Multip..
04/15 TOSHIBA : Landis+Gyr Technologies Assigned Patent
04/14 TOSHIBA : Develops Low Power Control Technology for Wearable Devices with Multip..
04/14 IBA : Joins Forces with Toshiba for Particle Therapy
04/14 IBA : and Toshiba Ink Strategic Partnership
04/13 TOSHIBA : Uninterruptible Power Systems Launches Mobile App for Android Devices
04/13 TOSHIBA : World first research-to-clinical platform enables quicker bench to bed..
04/13 TOSHIBA : Makes Healthcare IT Debut at HIMSS 2015
Advertisement
Chart
Duration : Period :
Toshiba Corp Technical Analysis Chart | 6502 | JP3592200004 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF